Carlo Lucchesi1, Emmanuel Khalifa2, Yec'han Laizet1, Isabelle Soubeyran2, Simone Mathoulin-Pelissier3,4,5,6, Christine Chomienne7, Antoine Italiano8,9. 1. Bioinformatics Unit, Institut Bergonié, 229 Cours de L'Argonne, 33076 Bordeaux, France. 2. Department of Pathology, Institut Bergonié, 229 Cours de L'Argonne, 33076 Bordeaux, France. 3. Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France. 4. Institut national de la santé et de la recherche médicale (INSERM),Clinical Epidemiology, Bordeaux, France. 5. INSERM, Institut de Santé Publique, d' Épidémiologie et de Développement (ISPED), Centre INSERM U1219 Bordeaux Population Health Center, Epicene Team, F-33000 Bordeaux, France. 6. University of Bordeaux, ISPED, Centre INSERM U1219 Bordeaux Population Health, Epicene Team, F-33000 Bordeaux, France. 7. L'Institut Thématique Multiorganisme Cancer, Bordeaux, France. 8. Department of Medical Oncology, Institut Bergonié, Bordeaux, France. 9. University of Bordeaux, France.
Abstract
Importance: Patients with advanced soft-tissue sarcomas (STS) have a median overall survival of less than 18 months. Identification of molecular abnormalities for which targeted therapies are available or can be developed is critical for improving patient outcomes. Objective: To characterize targetable genomic alterations (GAs) in patients with STS. Design, Setting, and Participants: This cross-sectional study of next-generation sequencing results from 584 patients with STS included in the AACR GENIE Database. Main Outcomes and Measures: Presence of targetable GAs in STS. Results: Of 584 patients included in the analysis, 294 (50.3%) were men and 290 (49.7%) were women, with a median age of 56 years (range, 18-89 years). There were 331 (57%) patients with complex genomics sarcomas, 144 (25%) with translocation-related sarcomas, and 112 (18%) with other sarcomas (inactivating mutation, simple amplicon). A total of 2697 alterations were identified in 451 genes (1154 substitutions, 765 gene amplifications, 364 short indels and splicing variants, 346 gene homozygous deletions, and 68 gene rearrangements) with a median of 4 (1-53) per case. In order of frequency, the 20 genes most often altered were: TP53, MDM2, CDK4, RB1, ATRX, CDKN2A, PTEN, NF1, CDKN2B, KMT2D, GLI1, ATM, TERT, PI3KCA, NOTCH1, MAP2K4, ERBB4, ARID1A, TSC2, and TNFAIP3. At least 1 targetable GA was found in 239 cases (41%) with a statistically significant higher number in other and complex genomics sarcomas than in translocation-related sarcomas (respectively other: n=89, 82%, complex: n = 131, 40%, translocation: n = 19, 13%; χ2 test, P < .001). Conclusions and Relevance: Up to 41% of STS harbored at least 1 clinically relevant GA with potential to influence and personalize therapy. Comprehensive genomic profiling can identify novel treatment paradigms to address the limited options and poor prognoses of patients with STS.
Importance: Patients with advanced soft-tissue sarcomas (STS) have a median overall survival of less than 18 months. Identification of molecular abnormalities for which targeted therapies are available or can be developed is critical for improving patient outcomes. Objective: To characterize targetable genomic alterations (GAs) in patients with STS. Design, Setting, and Participants: This cross-sectional study of next-generation sequencing results from 584 patients with STS included in the AACR GENIE Database. Main Outcomes and Measures: Presence of targetable GAs in STS. Results: Of 584 patients included in the analysis, 294 (50.3%) were men and 290 (49.7%) were women, with a median age of 56 years (range, 18-89 years). There were 331 (57%) patients with complex genomics sarcomas, 144 (25%) with translocation-related sarcomas, and 112 (18%) with other sarcomas (inactivating mutation, simple amplicon). A total of 2697 alterations were identified in 451 genes (1154 substitutions, 765 gene amplifications, 364 short indels and splicing variants, 346 gene homozygous deletions, and 68 gene rearrangements) with a median of 4 (1-53) per case. In order of frequency, the 20 genes most often altered were: TP53, MDM2, CDK4, RB1, ATRX, CDKN2A, PTEN, NF1, CDKN2B, KMT2D, GLI1, ATM, TERT, PI3KCA, NOTCH1, MAP2K4, ERBB4, ARID1A, TSC2, and TNFAIP3. At least 1 targetable GA was found in 239 cases (41%) with a statistically significant higher number in other and complex genomics sarcomas than in translocation-related sarcomas (respectively other: n=89, 82%, complex: n = 131, 40%, translocation: n = 19, 13%; χ2 test, P < .001). Conclusions and Relevance: Up to 41% of STS harbored at least 1 clinically relevant GA with potential to influence and personalize therapy. Comprehensive genomic profiling can identify novel treatment paradigms to address the limited options and poor prognoses of patients with STS.
Authors: Mandy L Ballinger; David L Goode; Isabelle Ray-Coquard; Paul A James; Gillian Mitchell; Eveline Niedermayr; Ajay Puri; Joshua D Schiffman; Gillian S Dite; Arcadi Cipponi; Robert G Maki; Andrew S Brohl; Ola Myklebost; Eva W Stratford; Susanne Lorenz; Sung-Min Ahn; Jin-Hee Ahn; Jeong Eun Kim; Sue Shanley; Victoria Beshay; Robert Lor Randall; Ian Judson; Beatrice Seddon; Ian G Campbell; Mary-Anne Young; Rajiv Sarin; Jean-Yves Blay; Seán I O'Donoghue; David M Thomas Journal: Lancet Oncol Date: 2016-08-04 Impact factor: 41.316
Authors: Jordi Barretina; Barry S Taylor; Shantanu Banerji; Alexis H Ramos; Mariana Lagos-Quintana; Penelope L Decarolis; Kinjal Shah; Nicholas D Socci; Barbara A Weir; Alan Ho; Derek Y Chiang; Boris Reva; Craig H Mermel; Gad Getz; Yevgenyi Antipin; Rameen Beroukhim; John E Major; Charles Hatton; Richard Nicoletti; Megan Hanna; Ted Sharpe; Tim J Fennell; Kristian Cibulskis; Robert C Onofrio; Tsuyoshi Saito; Neerav Shukla; Christopher Lau; Sven Nelander; Serena J Silver; Carrie Sougnez; Agnes Viale; Wendy Winckler; Robert G Maki; Levi A Garraway; Alex Lash; Heidi Greulich; David E Root; William R Sellers; Gary K Schwartz; Cristina R Antonescu; Eric S Lander; Harold E Varmus; Marc Ladanyi; Chris Sander; Matthew Meyerson; Samuel Singer Journal: Nat Genet Date: 2010-07-04 Impact factor: 38.330
Authors: Debyani Chakravarty; Jianjiong Gao; Sarah M Phillips; Ritika Kundra; Hongxin Zhang; Jiaojiao Wang; Julia E Rudolph; Rona Yaeger; Tara Soumerai; Moriah H Nissan; Matthew T Chang; Sarat Chandarlapaty; Tiffany A Traina; Paul K Paik; Alan L Ho; Feras M Hantash; Andrew Grupe; Shrujal S Baxi; Margaret K Callahan; Alexandra Snyder; Ping Chi; Daniel Danila; Mrinal Gounder; James J Harding; Matthew D Hellmann; Gopa Iyer; Yelena Janjigian; Thomas Kaley; Douglas A Levine; Maeve Lowery; Antonio Omuro; Michael A Postow; Dana Rathkopf; Alexander N Shoushtari; Neerav Shukla; Martin Voss; Ederlinda Paraiso; Ahmet Zehir; Michael F Berger; Barry S Taylor; Leonard B Saltz; Gregory J Riely; Marc Ladanyi; David M Hyman; José Baselga; Paul Sabbatini; David B Solit; Nikolaus Schultz Journal: JCO Precis Oncol Date: 2017-05-16
Authors: Nathan D Seligson; Esko A Kautto; Edward N Passen; Colin Stets; Amanda E Toland; Sherri Z Millis; Christian F Meyer; John L Hays; James L Chen Journal: Oncologist Date: 2018-12-12
Authors: Mrinal M Gounder; Narasimhan P Agaram; Sally E Trabucco; Victoria Robinson; Richard A Ferraro; Sherri Z Millis; Anita Krishnan; Jessica Lee; Steven Attia; Wassim Abida; Alexander Drilon; Ping Chi; Sandra P D' Angelo; Mark A Dickson; Mary Lou Keohan; Ciara M Kelly; Mark Agulnik; Sant P Chawla; Edwin Choy; Rashmi Chugh; Christian F Meyer; Parvathi A Myer; Jessica L Moore; Ross A Okimoto; Raphael E Pollock; Vinod Ravi; Arun S Singh; Neeta Somaiah; Andrew J Wagner; John H Healey; Garrett M Frampton; Jeffrey M Venstrom; Jeffrey S Ross; Marc Ladanyi; Samuel Singer; Murray F Brennan; Gary K Schwartz; Alexander J Lazar; David M Thomas; Robert G Maki; William D Tap; Siraj M Ali; Dexter X Jin Journal: Nat Commun Date: 2022-06-15 Impact factor: 17.694
Authors: Geraldine O'Sullivan Coyne; Shivaani Kummar; James Hu; Kristen Ganjoo; Warren A Chow; Khanh T Do; Jennifer Zlott; Ashley Bruns; Lawrence Rubinstein; Jared C Foster; Lamin Juwara; Robert Meehan; Richard Piekarz; Howard Streicher; Elad Sharon; Naoko Takebe; Andrea Regier Voth; Donald Bottaro; Rene Costello; John J Wright; James H Doroshow; Alice P Chen Journal: Clin Cancer Res Date: 2021-10-29 Impact factor: 13.801